Dana-Farber Research News 06.15.2026 - Report - MDSpire

Dana-Farber Research News 06.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from May 16 - 31.

  • By

  • June 15, 2026

  • 27 min

Share

Clinical Report: Dana-Farber Research News 06.15.2026

Background

The advancements in targeted therapies for cancer, particularly in HER2-positive and ALK-positive tumors, are crucial for improving patient outcomes. Understanding the efficacy and safety profiles of novel treatments like TAC01-HER2 and lorlatinib is essential.

Data Highlights

StudyFindings
TAC01-HER223 patients enrolled; 60.9% experienced cytokine release syndrome; 61.1% disease control rate.
Lorlatinib7-year PFS 55% vs 3% for crizotinib; median PFS not reached for lorlatinib.

Key Findings

  • TAC01-HER2 showed manageable toxicity with no treatment-related deaths.
  • Median progression-free survival for TAC01-HER2 was 2.6 months.
  • In the CROWN study, lorlatinib demonstrated a median PFS not reached compared to 9.1 months for crizotinib.
  • Patients on lorlatinib without progression at 24 months had a 79% probability of survival without progression at year 7.
  • New potential resistance mechanisms were identified in ctDNA samples from early progressors on lorlatinib.

Clinical Implications

The findings from the TAC01-HER2 trial indicate manageable side effects. The long-term outcomes observed with lorlatinib may provide data for future treatment considerations for patients with advanced ALK-positive NSCLC.

Conclusion

The research highlights the safety and efficacy profiles of TAC01-HER2 and lorlatinib.

Related Resources & Content

  1. Dana-Farber Research News 04.15.2026
  2. Dana-Farber Research News 02.15.2026
  3. Dana-Farber Research News 07.01.2025
  4. Dana-Farber Research News 03.15.2026
  5. Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death | Dana-Farber Cancer Institute
  6. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
  7. New ASCO Guideline Fills Gap in Guidance on Rapidly Evolving Treatment Options in Thyroid Cancer - The ASCO Post
  8. Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death | Dana-Farber Cancer Institute
  9. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline | ASCO Publications
  10. New ASCO Guideline Fills Gap in Guidance on Rapidly Evolving Treatment Options in Thyroid Cancer - The ASCO Post

Original Source(s)

Dana-Farber Research News 06.15.2026

  • by

  • June 15, 2026

Related Content

Prostatic incidental uptake on PET/CT: an updated systematic review and meta-analysis of prevalence and malignancy risk

The Role of Homeobox Genes in Signaling Pathway Positive Feedback Loops and Cancer Therapy

Leveraging Large Language Models to Integrate Clinical Knowledge and Machine Learning Predictions for Lymph Node Metastasis Prediction: Development of a Knowledge-Augmented Framework